Osteoclasts in Osteosarcoma: Mechanisms, Interactions, and Therapeutic Prospects

References

• Ritter J, Bielack SS. Osteosarcoma. Ann Oncol. 2010;21(Suppl 7):vii320–5. doi:10.1093/annonc/mdq276
   PubMed Web of Science ®Google Scholar
• Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program. Cancer. 2009;115(7):1531–1543. doi:10.1002/cncr.24121
   PubMed Web of Science ®Google Scholar
• Whelan JS, Davis LE. Osteosarcoma, chondrosarcoma, and chordoma. J Clin Oncol. 2018;36(2):188–193. doi:10.1200/JCO.2017.75.1743
   PubMed Web of Science ®Google Scholar
• Lu Y, Zhang J, Chen Y, et al. Novel immunotherapies for osteosarcoma. Front Oncol. 2022;12:830546. doi:10.3389/fonc.2022.830546
   PubMedGoogle Scholar
• Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol. 2015;33(27):3029–3035. doi:10.1200/JCO.2014.59.4895
   PubMed Web of Science ®Google Scholar
• Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20(3):776–790. doi:10.1200/JCO.2002.20.3.776
   PubMed Web of Science ®Google Scholar
• Yu X, Yustein JT, Xu J. Research models and mesenchymal/epithelial plasticity of osteosarcoma. Cell Biosci. 2021;11(1):94. doi:10.1186/s13578-021-00600-w
   PubMed Web of Science ®Google Scholar
• Stiller CA, Bielack SS, Jundt G, Steliarova-Foucher E. Bone tumours in European children and adolescents, 1978–1997. Report from the automated childhood cancer information system project. Eur J Cancer. 2006;42(13):2124–2135. doi:10.1016/j.ejca.2006.05.015
   PubMed Web of Science ®Google Scholar
• Kassir RR, Rassekh CH, Kinsella JB, Segas J, Carrau RL, Hokanson JA. Osteosarcoma of the head and neck: meta-analysis of nonrandomized studies. Laryngoscope. 1997;107(1):56–61. doi:10.1097/00005537-199701000-00013
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi:10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• Wu Y, Xie Z, Chen J, et al. Circular RNA circTADA2A promotes osteosarcoma progression and metastasis by sponging miR-203a-3p and regulating CREB3 expression. Mol Cancer. 2019;18(1):73. doi:10.1186/s12943-019-1007-1
   PubMed Web of Science ®Google Scholar
• Yang B, Li L, Tong G, et al. Circular RNA circ_001422 promotes the progression and metastasis of osteosarcoma via the miR-195-5p/FGF2/PI3K/Akt axis. J Exp Clin Cancer Res. 2021;40(1):235. doi:10.1186/s13046-021-02027-0
   PubMed Web of Science ®Google Scholar
• Wen M, Ren H, Zhang S, Li T, Zhang J, Ren P. CT45A1 promotes the metastasis of osteosarcoma cells in vitro and in vivo through beta-catenin. Cell Death Dis. 2021;12(7):650. doi:10.1038/s41419-021-03935-x
   PubMed Web of Science ®Google Scholar
• Yang C, Tian Y, Zhao F, et al. Bone microenvironment and osteosarcoma metastasis. Int J Mol Sci. 2020;21(19). doi:10.3390/ijms21196985
   Web of Science ®Google Scholar
• Boyce BF. Advances in the regulation of osteoclasts and osteoclast functions. J Dent Res. 2013;92(10):860–867. doi:10.1177/0022034513500306
   PubMed Web of Science ®Google Scholar
• Chen X, Wang Z, Duan N, Zhu G, Schwarz EM, Xie C. Osteoblast-osteoclast interactions. Connect Tissue Res. 2018;59(2):99–107. doi:10.1080/03008207.2017.1290085
   PubMed Web of Science ®Google Scholar
• Park-Min KH. Metabolic reprogramming in osteoclasts. Semin Immunopathol. 2019;41(5):565–572. doi:10.1007/s00281-019-00757-0
   PubMed Web of Science ®Google Scholar
• Eriksen EF. Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord. 2010;11(4):219–227. doi:10.1007/s11154-010-9153-1
   PubMed Web of Science ®Google Scholar
• Bago-Horvath Z, Schmid K, Rossler F, Nagy-Bojarszky K, Funovics P, Sulzbacher I. Impact of RANK signalling on survival and chemotherapy response in osteosarcoma. Pathology. 2014;46(5):411–415. doi:10.1097/PAT.0000000000000116
   PubMed Web of Science ®Google Scholar
• Honma M, Ikebuchi Y, Suzuki H. RANKL as a key figure in bridging between the bone and immune system: its physiological functions and potential as a pharmacological target. Pharmacol Ther. 2021;218:107682. doi:10.1016/j.pharmthera.2020.107682
   PubMed Web of Science ®Google Scholar
• Hancox NM. The osteoclast. Biol Rev Camb Philos Soc. 1949;24(4):448–471. doi:10.1111/j.1469-185x.1949.tb00583.x
   PubMed Web of Science ®Google Scholar
• Sun Y, Li J, Xie X, et al. Macrophage-osteoclast associations: origin, polarization, and subgroups. Front Immunol. 2021;12:778078. doi:10.3389/fimmu.2021.778078
   PubMed Web of Science ®Google Scholar
• Yao Y, Cai X, Ren F, et al. The macrophage-osteoclast axis in osteoimmunity and osteo-related diseases. Front Immunol. 2021;12:664871. doi:10.3389/fimmu.2021.664871
   PubMed Web of Science ®Google Scholar
• Walker DG. Spleen cells transmit osteopetrosis in mice. Science. 1975;190(4216):785–787. doi:10.1126/science.1198094
   PubMed Web of Science ®Google Scholar
• Yang D, Wan Y. Molecular determinants for the polarization of macrophage and osteoclast. Semin Immunopathol. 2019;41(5):551–563. doi:10.1007/s00281-019-00754-3
   PubMed Web of Science ®Google Scholar
• Schlundt C, Fischer H, Bucher CH, Rendenbach C, Duda GN, Schmidt-Bleek K. The multifaceted roles of macrophages in bone regeneration: a story of polarization, activation and time. Acta Biomater. 2021;133:46–57. doi:10.1016/j.actbio.2021.04.052
   PubMed Web of Science ®Google Scholar
• Nakashima T, Hayashi M, Takayanagi H. New insights into osteoclastogenic signaling mechanisms. Trends Endocrinol Metab. 2012;23(11):582–590. doi:10.1016/j.tem.2012.05.005
   PubMed Web of Science ®Google Scholar
• Ono T, Hayashi M, Sasaki F, Nakashima T. RANKL biology: bone metabolism, the immune system, and beyond. Inflamm Regen. 2020;40:2. doi:10.1186/s41232-019-0111-3
   PubMed Web of Science ®Google Scholar
• Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther. 2007;9(Suppl 1):S1. doi:10.1186/ar2165
   PubMed Web of Science ®Google Scholar
• Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone. 1999;25(3):255–259. doi:10.1016/s8756-3282(99)00162-3
   PubMed Web of Science ®Google Scholar
• Yi SJ, Jang YJ, Kim HJ, et al. The KDM4B-CCAR1-MED1 axis is a critical regulator of osteoclast differentiation and bone homeostasis. Bone Res. 2021;9(1):27. doi:10.1038/s41413-021-00145-1
   PubMed Web of Science ®Google Scholar
• Yao Z, Getting SJ, Locke IC. Regulation of TNF-induced osteoclast differentiation. Cells. 2021;11(1). doi:10.3390/cells11010132
   Web of Science ®Google Scholar
• Chiu YH, Ritchlin CT. DC-STAMP: a key regulator in osteoclast differentiation. J Cell Physiol. 2016;231(11):2402–2407. doi:10.1002/jcp.25389
   PubMed Web of Science ®Google Scholar
• Kim H, Oh B, Park-Min KH. Regulation of osteoclast differentiation and activity by lipid metabolism. Cells. 2021;10(1). doi:10.3390/cells10010089
   Web of Science ®Google Scholar
• Yang W, Han W, Qin A, Wang Z, Xu J, Qian Y. The emerging role of Hippo signaling pathway in regulating osteoclast formation. J Cell Physiol. 2018;233(6):4606–4617. doi:10.1002/jcp.26372
   PubMed Web of Science ®Google Scholar
• Sun Y, Li J, Xie X, et al. Recent advances in osteoclast biological behavior. Front Cell Dev Biol. 2021;9:788680. doi:10.3389/fcell.2021.788680
   PubMed Web of Science ®Google Scholar
• Vaananen K. Mechanism of osteoclast mediated bone resorption--rationale for the design of new therapeutics. Adv Drug Deliv Rev. 2005;57(7):959–971. doi:10.1016/j.addr.2004.12.018
   PubMed Web of Science ®Google Scholar
• Liu X, Chai Y, Liu G, et al. Osteoclasts protect bone blood vessels against senescence through the angiogenin/plexin-B2 axis. Nat Commun. 2021;12(1):1832. doi:10.1038/s41467-021-22131-1
   PubMed Web of Science ®Google Scholar
• Xie H, Cui Z, Wang L, et al. PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis. Nat Med. 2014;20(11):1270–1278. doi:10.1038/nm.3668
   PubMed Web of Science ®Google Scholar
• Hadjidakis DJ, Androulakis II. Bone remodeling. Ann N Y Acad Sci. 2006;1092:385–396. doi:10.1196/annals.1365.035
   PubMed Web of Science ®Google Scholar
• Gu DR, Yang H, Kim SC, Hwang YH, Ha H. Water extract of piper longum Linn ameliorates ovariectomy-induced bone loss by inhibiting osteoclast differentiation. Nutrients. 2022;14(17):3667. doi:10.3390/nu14173667
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Yoshida H, Tanaka S. Role of interleukin-6 in bone destruction and bone repair in rheumatoid arthritis. Autoimmun Rev. 2021;20(9):102884. doi:10.1016/j.autrev.2021.102884
   PubMed Web of Science ®Google Scholar
• Qu H, Zhuang Y, Zhu L, Zhao Z, Wang K. The effects of vasoactive intestinal peptide on RANKL-induced osteoclast formation. Ann Transl Med. 2021;9(2):127. doi:10.21037/atm-20-7607
   PubMed Web of Science ®Google Scholar
• Sobacchi C, Abinun M. Osteoclast-poor osteopetrosis. Bone. 2022;164:116541. doi:10.1016/j.bone.2022.116541
   PubMed Web of Science ®Google Scholar
• Han Y, Feng H, Sun J, et al. Lkb1 deletion in periosteal mesenchymal progenitors induces osteogenic tumors through mTORC1 activation. J Clin Invest. 2019;129(5):1895–1909. doi:10.1172/JCI124590
   PubMed Web of Science ®Google Scholar
• Luxenburg C, Geblinger D, Klein E, et al. The architecture of the adhesive apparatus of cultured osteoclasts: from podosome formation to sealing zone assembly. PLoS One. 2007;2(1):e179. doi:10.1371/journal.pone.0000179
   PubMed Web of Science ®Google Scholar
• Teitelbaum SL. Osteoclasts: what do they do and how do they do it? Am J Pathol. 2007;170(2):427–435. doi:10.2353/ajpath.2007.060834
   PubMed Web of Science ®Google Scholar
• Deligiorgi MV, Panayiotidis MI, Griniatsos J, Trafalis DT. Harnessing the versatile role of OPG in bone oncology: counterbalancing RANKL and TRAIL signaling and beyond. Clin Exp Metastasis. 2020;37(1):13–30. doi:10.1007/s10585-019-09997-8
   PubMed Web of Science ®Google Scholar
• Akiyama T, Dass CR, Choong PF. Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway. Mol Cancer Ther. 2008;7(11):3461–3469. doi:10.1158/1535-7163.MCT-08-0530
   PubMed Web of Science ®Google Scholar
• Luo T, Zhou X, Jiang E, Wang L, Ji Y, Shang Z. Osteosarcoma cell-derived small extracellular vesicles enhance osteoclastogenesis and bone resorption through transferring MicroRNA-19a-3p. Front Oncol. 2021;11:618662. doi:10.3389/fonc.2021.618662
   PubMed Web of Science ®Google Scholar
• Lin L, Wang H, Guo W, He E, Huang K, Zhao Q. Osteosarcoma-derived exosomal miR-501-3p promotes osteoclastogenesis and aggravates bone loss. Cell Signal. 2021;82:109935. doi:10.1016/j.cellsig.2021.109935
   PubMed Web of Science ®Google Scholar
• Endo-Munoz L, Cumming A, Rickwood D, et al. Loss of osteoclasts contributes to development of osteosarcoma pulmonary metastases. Cancer Res. 2010;70(18):7063–7072. doi:10.1158/0008-5472.CAN-09-4291
   PubMed Web of Science ®Google Scholar
• Jiang N, Guo F, Xu W, et al. Effect of fluoride on osteocyte-driven osteoclastic differentiation. Toxicology. 2020;436:152429. doi:10.1016/j.tox.2020.152429
   PubMed Web of Science ®Google Scholar
• Avnet S, Longhi A, Salerno M, et al. Increased osteoclast activity is associated with aggressiveness of osteosarcoma. Int J Oncol. 2008;33(6):1231–1238.
   PubMed Web of Science ®Google Scholar
• Zhu L, Tang Y, Li XY, et al. Osteoclast-mediated bone resorption is controlled by a compensatory network of secreted and membrane-tethered metalloproteinases. Sci Transl Med. 2020;12(529). doi:10.1126/scitranslmed.aaw6143
   Web of Science ®Google Scholar
• Tan J, Dai A, Pan L, et al. Inflamm-aging-related cytokines of IL-17 and IFN-gamma accelerate osteoclastogenesis and periodontal destruction. J Immunol Res. 2021;2021:9919024. doi:10.1155/2021/9919024
   PubMed Web of Science ®Google Scholar
• Zhou Y, Yang D, Yang Q, et al. Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma. Nat Commun. 2020;11(1):6322. doi:10.1038/s41467-020-20059-6
   PubMed Web of Science ®Google Scholar
• Zhou Q, Xian M, Xiang S, et al. All-trans retinoic acid prevents osteosarcoma metastasis by inhibiting M2 polarization of tumor-associated macrophages. Cancer Immunol Res. 2017;5(7):547–559. doi:10.1158/2326-6066.CIR-16-0259
   PubMed Web of Science ®Google Scholar
• Kelleher FC, O’Sullivan H. Monocytes, macrophages, and osteoclasts in osteosarcoma. J Adolesc Young Adult Oncol. 2017;6(3):396–405. doi:10.1089/jayao.2016.0078
   PubMed Web of Science ®Google Scholar
• Spencer GJ, Utting JC, Etheridge SL, Arnett TR, Genever PG. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci. 2006;119(Pt 7):1283–1296. doi:10.1242/jcs.02883
   PubMed Web of Science ®Google Scholar
• Wang J, Sun J, Liu LN, et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat Med. 2019;25(4):656–666. doi:10.1038/s41591-019-0374-x
   PubMed Web of Science ®Google Scholar
• Zhen G, Dan Y, Wang R, et al. An antibody against Siglec-15 promotes bone formation and fracture healing by increasing TRAP(+) mononuclear cells and PDGF-BB secretion. Bone Res. 2021;9(1):47. doi:10.1038/s41413-021-00161-1
   PubMed Web of Science ®Google Scholar
• Dou C, Zhen G, Dan Y, Wan M, Limjunyawong N, Cao X. Sialylation of TLR2 initiates osteoclast fusion. Bone Res. 2022;10(1):24. doi:10.1038/s41413-022-00186-0
   PubMed Web of Science ®Google Scholar
• Groth C, Hu X, Weber R, et al. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer. 2019;120(1):16–25. doi:10.1038/s41416-018-0333-1
   PubMed Web of Science ®Google Scholar
• Ohl K, Tenbrock K. Reactive oxygen species as regulators of MDSC-mediated immune suppression. Front Immunol. 2018;9:2499. doi:10.3389/fimmu.2018.02499
   PubMed Web of Science ®Google Scholar
• Yaseen MM, Abuharfeil NM, Darmani H, Daoud A. Recent advances in myeloid-derived suppressor cell biology. Front Med. 2021;15(2):232–251. doi:10.1007/s11684-020-0797-2
   PubMed Web of Science ®Google Scholar
• Ling Z, Yang C, Tan J, Dou C, Chen Y. Beyond immunosuppressive effects: dual roles of myeloid-derived suppressor cells in bone-related diseases. Cell Mol Life Sci. 2021;78(23):7161–7183. doi:10.1007/s00018-021-03966-9
   PubMed Web of Science ®Google Scholar
• Sawant A, Ponnazhagan S. Myeloid-derived suppressor cells as osteoclast progenitors: a novel target for controlling osteolytic bone metastasis. Cancer Res. 2013;73(15):4606–4610. doi:10.1158/0008-5472.CAN-13-0305
   PubMed Web of Science ®Google Scholar
• Uehara T, Eikawa S, Nishida M, et al. Metformin induces CD11b+-cell-mediated growth inhibition of an osteosarcoma: implications for metabolic reprogramming of myeloid cells and anti-tumor effects. Int Immunol. 2019;31(4):187–198. doi:10.1093/intimm/dxy079
   PubMed Web of Science ®Google Scholar
• Jiang K, Li J, Zhang J, et al. SDF-1/CXCR4 axis facilitates myeloid-derived suppressor cells accumulation in osteosarcoma microenvironment and blunts the response to anti-PD-1 therapy. Int Immunopharmacol. 2019;75:105818. doi:10.1016/j.intimp.2019.105818
   PubMed Web of Science ®Google Scholar
• Yu L, Guo W, Zhao S, Wang F, Xu Y. Fusion between cancer cells and myofibroblasts is involved in osteosarcoma. Oncol Lett. 2011;2(6):1083–1087. doi:10.3892/ol.2011.363
   PubMed Web of Science ®Google Scholar
• Walsh NC, Alexander KA, Manning CA, et al. Activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL. Genes Immun. 2013;14(5):336–345. doi:10.1038/gene.2013.29
   PubMed Web of Science ®Google Scholar
• Monteiro AC, Bonomo A. Dendritic cells development into osteoclast-type APCs by 4T1 breast tumor T cells milieu boost bone consumption. Bone. 2021;143:115755. doi:10.1016/j.bone.2020.115755
   PubMed Web of Science ®Google Scholar
• Bellini G, Di Pinto D, Tortora C, et al. The role of mifamurtide in chemotherapy-induced osteoporosis of children with osteosarcoma. Curr Cancer Drug Targets. 2017;17(7):650–656. doi:10.2174/1568009616666161215163426
   PubMed Web of Science ®Google Scholar
• Munoz-Garcia J, Vargas-Franco JW, Royer BB, et al. Inhibiting endothelin receptors with macitentan strengthens the bone protective action of RANKL inhibition and reduces metastatic dissemination in osteosarcoma. Cancers (Basel). 2022;14(7). doi:10.3390/cancers14071765
   Web of Science ®Google Scholar
• Lu KH, Lu EW, Lin CW, Yang JS, Yang SF. New insights into molecular and cellular mechanisms of zoledronate in human osteosarcoma. Pharmacol Ther. 2020;214:107611. doi:10.1016/j.pharmthera.2020.107611
   PubMed Web of Science ®Google Scholar
• Sturge J. Endo180 at the cutting edge of bone cancer treatment and beyond. J Pathol. 2016;238(4):485–488. doi:10.1002/path.4673
   PubMed Web of Science ®Google Scholar
• Shao H, Ge M, Zhang J, Zhao T, Zhang S. Osteoclasts differential-related prognostic biomarker for osteosarcoma based on single cell, bulk cell and gene expression datasets. BMC Cancer. 2022;22(1):288. doi:10.1186/s12885-022-09380-z
   PubMed Web of Science ®Google Scholar
• Ahern E, Smyth MJ, Dougall WC, Teng MWL. Roles of the RANKL-RANK axis in antitumour immunity - implications for therapy. Nat Rev Clin Oncol. 2018;15(11):676–693. doi:10.1038/s41571-018-0095-y
   PubMed Web of Science ®Google Scholar
• Araki Y, Yamamoto N, Hayashi K, et al. The number of osteoclasts in a biopsy specimen can predict the efficacy of neoadjuvant chemotherapy for primary osteosarcoma. Sci Rep. 2021;11(1):1989. doi:10.1038/s41598-020-80504-w
   PubMed Web of Science ®Google Scholar